Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect

@article{Miguellvarez2015NonSteroidalAD,
  title={Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect},
  author={Marina Miguel-{\'A}lvarez and Alejandro Santos-Lozano and Fabi{\'a}n Sanchis-Gomar and Carmen Fiuza-Luces and Helios Pareja-Galeano and Nuria Garatachea and Alejandro Lucia},
  journal={Drugs \& Aging},
  year={2015},
  volume={32},
  pages={139-147}
}
IntroductionAlzheimer’s disease (AD) is the cause of more than two-thirds of all dementia cases. Although there is no effective treatment against this disorder, its association with neuroinflammation suggests that non-steroidal anti-inflammatory drugs (NSAIDs) might represent a potential therapeutic option.ObjectiveThe objective of this study was to evaluate the efficacy of NSAIDs in the treatment of AD using a meta-analysis approach.MethodsMEDLINE, Web of Science, Science Direct, and the… Expand
Recommendations for Anti-inflammatory Treatments in Alzheimer’s Disease: A Comprehensive Review of the Literature
TLDR
This article provides a comprehensive review of various observational studies and randomized trials encompassing the use of anti-inflammatory agents in the management of AD patients and utilizes the conclusions derived therefrom to give recommendations in this regard. Expand
Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease
TLDR
A dose–response meta-analysis showed that nonsteroidal anti-inflammatory drugs (NSAIDs) use was not associated with Parkinson disease risk, and the potency and the cumulative NSAIDs use did not play critical roles. Expand
Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?
  • A. Cuello
  • Medicine
  • Trends in pharmacological sciences
  • 2017
TLDR
It is postulated that the explanation for the success of NSAIDS in preventing AD onset when given at preclinical stages, and for their failure when administered after AD clinical presentation, lies in the changing nature of central nervous system (CNS) inflammation in the decades-long continuum of AD pathology. Expand
Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines
TLDR
It is suggested that it is crucial for both the pharmacological and complementary medicine industries to conduct and fund studies to significantly advance the field of anti-inflammatory drugs and phytomedicines, as it is not yet clear if the active compounds reach an effective concentration in the brain or if they can slow down AD progression in long-term trials. Expand
Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease
TLDR
The objective of this review is to discuss the advantages and potential therapeutic value of positive allosteric modulators (PAMs) of the nAChRs in halting or delaying the progression of AD by diminishing neuroinflammation, abnormal protein aggregation and synaptic dysfunction. Expand
Targeting Neuroin fl ammation as a Therapeutic Strategy for Alzheimer ’ s Disease : Mechanisms , Drug Candidates , and New Opportunities
Alzheimer’s disease is a progressive neurodegenerative disease, and its incidence is expected to increase owing to the aging population worldwide. Current therapies merely provide symptomatic relief.Expand
Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database
TLDR
Long term use of oral non-steroidal anti-inflammatory drugs (NSAIDs) is linked with reduced risk of developing Alzheimer’s disease, and data from MedWatch suggest that fluticasone propionate administered intranasally might have a similar preventive effect to ibuprofen. Expand
Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
TLDR
DR approaches will create a major paradigm shift in AD research and development, with relatively homogeneous AD subpopulations specifically targeted with existing drugs based on known modes of action. Expand
Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities.
TLDR
The mechanisms and status of different anti-inflammatory drug candidates for AD that have undergone or are undergoing clinical trials are discussed and new opportunities for targeting neuroinflammation in AD drug development are explored. Expand
Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease.
TLDR
The influence of cellular mediators which are involved in the NI process, with regards to the progression of AD are represented and multiple anti-inflammatory agents used in AD and have gone through or going through clinical trials are discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
TLDR
Based on analysis of prospective and nonprospective studies, NSAID exposure was associated with decreased risk of Alzheimer’s disease, and an issue that requires further exploration in future trials or observational studies is the temporal relationship betweenNSAID exposure and protection against Alzheimer's disease. Expand
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies
TLDR
Systematic review and meta-analysis of observational studies published between 1966 and October 2002 that examined the role of NSAID use in preventing Alzheimer's disease found NSAIDs offer some protection against the development of Alzheimer's Disease. Expand
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease
TLDR
Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD. Expand
The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease
  • P. Aisen
  • Medicine
  • The Lancet Neurology
  • 2002
TLDR
There is not yet any strong evidence from completed randomised controlled trials that anti-inflammatory treatment is beneficial, but basic research studies provide substantial evidence that inflammatory processes present in the brains of patients with AD are destructive, and that pro-inflammatory drugs can provide protection. Expand
Rofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study
TLDR
The failure of selective cyclo-oxygenase–2 inhibition to slow the progression of AD may indicate either that the disease process is too advanced to modify in patients with established dementia or that cyclo’s enzyme does not play a significant role in the pathogenesis of the disorder. Expand
Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease
TLDR
Estimation of the overall chance of individuals exposed to arthritis or anti-inflammatory drugs developing AD as compared with the general population and population-based studies with rheumatoid arthritis and NSAID use as risk factors suggest anti- inflammatory drugs may have a protective effect against AD. Expand
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
TLDR
The results of this study indicate that rofecoxib or low-dose naproxen does not slow cognitive decline in patients with mild-to-moderate AD. Expand
No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial
TLDR
The results of this study are inconclusive with respect to the hypothesis that indomethacin slows the progression of AD. Expand
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
TLDR
This pilot study, with small treatment numbers, did not demonstrate a significant effect of NSAID treatment in AD, but the trends observed justify further investigations with a larger number of participants. Expand
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
TLDR
Celecoxib 200 mg bid did not slow the progression of AD in this study, and the occurrence of adverse events was as expected for an elderly population with a complex chronic medical condition. Expand
...
1
2
3
4
5
...